Clinical Trials Directory

Trials / Completed

CompletedNCT02635256

Hypofractionated Radiosurgery for Localised Prostate Cancer

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
85 (actual)
Sponsor
University Hospital Schleswig-Holstein · Academic / Other
Sex
Male
Age
60 Years
Healthy volunteers
Not accepted

Summary

Hypofractionated radiosurgery has been investigated in a few trials and appears to be safe and feasible. Investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 5 fractions in patients with localised prostate cancer, who are ineligible for the "PREFERE trial" under the hypothesis that the ratio of patients with late toxicity ≥ grade 2 after 1 year amounts 2,8% and is significant lower than 17.5%.

Detailed description

Experimental radiosurgery of prostate with 5 fractions each with 7,00 Gy (total application rate of 35,00 Gy). Planned visits are: Baseline, visits at every radiation day and four follow ups (4-6 weeks, 3 months, 6 months and one year after last day of radiation).

Conditions

Interventions

TypeNameDescription
RADIATIONHypofractionated RadiosurgeryImage-guided stereotactic Linac based RT preferable with "dedicated radiosurgery system" such as CyberKnife

Timeline

Start date
2015-12-01
Primary completion
2018-12-31
Completion
2019-12-31
First posted
2015-12-18
Last updated
2024-03-21

Locations

5 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT02635256. Inclusion in this directory is not an endorsement.

Hypofractionated Radiosurgery for Localised Prostate Cancer (NCT02635256) · Clinical Trials Directory